#Geographic Atrophy Market Size

[health-views-updates]

Comprehensive Geographic Atrophy Market Analysis: Size, Share, and Industry Growth

Geographic Atrophy Market Revenue is expected to witness substantial growth over the coming years as new therapies and treatments emerge to meet the needs of the growing number of individuals affected by this advanced form of age-related macular degeneration (AMD). Geographic atrophy, marked by irreversible retinal cell damage leading to vision loss, has spurred the need for innovative solutions and the development of novel therapeutic approaches. The market report by SNS Insider sheds light on the rising incidence of geographic atrophy and examines key industry dynamics, emerging treatment modalities, and ongoing advancements in therapeutic interventions that are expected to reshape the landscape of GA management globally.

As aging populations increase globally, so too does the prevalence of geographic atrophy, driving robust growth in the GA market. The rise in geriatric populations worldwide, especially in developed regions like North America and Europe, has escalated the demand for effective treatments to manage GA's impact on patients' quality of life. This market analysis explores the latest breakthroughs in geographic atrophy treatment, such as complement inhibition and regenerative therapies, which are making promising strides toward slowing disease progression and preserving vision. Industry players are heavily investing in research and development to bring these advanced therapies to market, with several promising candidates in clinical trials.

The report further highlights the pivotal role of regulatory support, research funding, and collaborative efforts among pharmaceutical companies, research institutions, and healthcare providers to expedite the development and approval of new GA therapies. The growing need for early diagnosis and treatment of geographic atrophy has led to increased investment in advanced diagnostic technologies, which will be crucial in shaping the future of patient care and market growth in the GA industry.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/2480

Key Drivers Fueling Geographic Atrophy Market Expansion

Technological Advancements in Diagnostics and Treatment Technological innovations have led to the development of advanced diagnostic tools and imaging modalities that aid in the early detection and accurate monitoring of GA progression. Enhanced diagnostics, such as optical coherence tomography (OCT) and fundus autofluorescence imaging, are vital in understanding the underlying disease mechanisms and assessing patient-specific treatment responses. The increased utilization of these cutting-edge diagnostic solutions by healthcare providers is anticipated to support the growth of the geographic atrophy market significantly.

Growing Focus on Complement Pathway Inhibition Complement pathway inhibition represents a promising therapeutic strategy in GA treatment. Research has identified that targeting specific components of the complement system can potentially slow the progression of geographic atrophy. Several companies are now focusing on developing therapies that act on these pathways, including ongoing clinical trials that are showing favorable results in delaying disease progression. Complement pathway inhibitors could become a major breakthrough in GA therapy, with approvals anticipated in the near future.

Increased R&D Investments and Strategic Partnerships Industry leaders are increasing their R&D investments to accelerate the development of novel GA therapies. In recent years, there has been a surge in strategic partnerships and collaborations, both within the pharmaceutical sector and with academic institutions, aimed at advancing GA research. These collaborations are helping to bridge knowledge gaps and expedite the development of new therapeutic candidates, pushing the market toward rapid growth. Moreover, public and private funding support has proven instrumental in advancing research and development activities, resulting in a growing pipeline of innovative treatments for GA.

Regional Insights and Competitive Landscape

The geographic atrophy market report from SNS Insider delves into regional trends, highlighting significant market share concentration in North America and Europe. These regions lead the market due to the high prevalence of age-related macular degeneration and greater healthcare expenditure on innovative treatments. The Asia-Pacific region, however, is projected to experience notable growth over the forecast period due to its expanding healthcare infrastructure, increased disease awareness, and rising demand for advanced therapeutic options.

With an increasingly competitive landscape, major pharmaceutical companies are working toward obtaining regulatory approvals for GA therapies and expanding their portfolios to capture the growing demand. Companies like Apellis Pharmaceuticals and Iveric Bio are at the forefront of this development, and the report provides a comprehensive analysis of their competitive strategies, product pipelines, and recent advancements in the GA market.

Market Outlook and Future Potential

The future of the geographic atrophy market looks promising, driven by the increasing incidence of GA, aging demographics, and continued advancements in therapeutic research. While challenges remain, such as the high cost of treatments and limited awareness in certain regions, the ongoing innovations in GA management, particularly in regenerative and gene therapies, are anticipated to create new avenues for growth in the market. The market is also poised to benefit from improved reimbursement policies and enhanced healthcare infrastructure, especially in emerging economies.

The report concludes by emphasizing the importance of continued research, stakeholder collaborations, and patient awareness initiatives in advancing GA treatment options. With a commitment to addressing the unmet needs of GA patients, the market is set for a transformative period that promises significant improvements in patient care and quality of life.

About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us: Akash Anand – Head of Business Development & Strategy info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[latestmarketresearchnews]

Aptamers Market - Structure, Size, Trends, Analysis and Outlook 2030

The global aptamers market was valued at USD 1.94 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 24.54% from 2023 to 2030. This rapid growth is being driven by significant advancements in the development, purification, and drug delivery systems for targeting and eliminating harmful cells, which have garnered the attention of researchers. Aptamers possess several competitive advantages over traditional antibodies, including smaller molecular size, lower immunogenicity (reduced immune response), reduced manufacturing costs, and fewer side effects. These benefits are encouraging research and development (R&D) efforts in the creation of new aptamers, fueling market expansion.

Despite considerable research, no highly effective treatments for COVID-19 have been identified, partly due to the virus's extensive genetic mutations. However, biotechnological approaches, including the use of aptamers, hold promise in combating COVID-19 infections. Nucleic acid-based aptamers and peptide aptamers are believed to offer potential therapeutic solutions for the virus, and various government initiatives are supporting the development of novel treatments for COVID-19. For example, in September 2020, the Department of Community & Economic Development awarded USD 320,000 to Aptagen LLC to fund research and development of a novel COVID-19 treatment. This investment reflects the growing recognition of aptamers' potential in addressing unmet medical needs.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Aptamers are also proving valuable in diagnostics. Using SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology, aptamer-based diagnostic kits and assays can develop high-affinity neutralizers and bioprobes for detecting SARS-CoV-2 and other COVID-19 biomarkers. These innovations are expected to further drive market growth. For example, in December 2021, Achiko AG received approval from the Indonesian Ministry of Health for its COVID-19 diagnostic kit, Aptamex. Aptamex is a second-generation, cost-effective diagnostic tool based on DNA aptamer technology, representing an emerging solution in healthcare diagnostics.

Type Segmentation Insights:

The aptamers market is segmented into nucleic acid aptamers and peptide aptamers. In 2022, the nucleic acid aptamers segment dominated the market, holding a 78.19% share, and is expected to exhibit the highest growth during the forecast period. Many companies are actively exploring the therapeutic mechanisms of nucleic acid aptamers for treating various disorders, such as age-related macular degeneration (AMD). For instance, in June 2021, the U.S. Food and Drug Administration (FDA) granted IVERIC BIO (formerly Ophthotech Corporation) a written agreement under the Special Protocol Assessment (SPA) for the design of its phase 3 clinical trial, GATHER2. The trial aims to assess the efficacy of Zimura, a nucleic acid aptamer-based drug, for patients with geographic atrophy (GA) secondary to AMD. This FDA approval is expected to significantly bolster the growth of the nucleic acid aptamer segment.

The peptide aptamer segment is anticipated to experience substantial growth, with a projected CAGR of 22.77% from 2023 to 2030, driven by its broad applications in diagnostics and therapeutics. For instance, in August 2021, scientists from the Engineering Center for Microtechnology and Diagnostics developed an innovative biosensor for multiparametric express testing in the preclinical diagnostics of cardiovascular diseases. This testing uses next-generation biochips, which are based on a peptide aptamer marker system and molecular recognition technology. The researchers designed peptide aptamers using data from the Data Bank and Protein 3D software. The introduction of such advanced products in the market is likely to increase the utilization of peptide aptamers, contributing to the segment's growth.

In summary, the aptamers market is poised for rapid expansion due to the advantages of aptamers in therapeutic and diagnostic applications, advancements in technology, and ongoing R&D efforts. The market's growth is further supported by government initiatives, regulatory approvals, and the increasing use of aptamer-based solutions in areas such as COVID-19 treatment, diagnostics, and the management of other medical conditions.

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[wellnessweb]

Innovative Strategies: Impacting Spinal Muscular Atrophy Treatment Market Size

The Spinal Muscular Atrophy Treatment Market size was estimated USD 4.2billion in 2022 and is expected to reach USD 7.1 billion by 2030 at a CAGR of 6.9% during the forecast period of 2023-2030.In the dynamic landscape of healthcare, the Spinal Muscular Atrophy (SMA) treatment market emerges as a beacon of hope, characterized by a convergence of groundbreaking therapies and innovative approaches. With a keen focus on addressing the underlying genetic mutations responsible for this debilitating neuromuscular disorder, the market showcases a diverse array of treatment modalities ranging from gene replacement therapies to small molecule interventions. Pioneering advancements in gene editing technologies, such as CRISPR-Cas9, have spurred a new wave of precision medicine, offering tailored solutions to patients across varying disease severities. Additionally, collaborative efforts between pharmaceutical companies, research institutions, and advocacy groups have propelled clinical trials forward, accelerating the pace of therapeutic development. As the therapeutic landscape continues to evolve, driven by a commitment to improving patient outcomes and quality of life, the SMA treatment market stands as a testament to the transformative power of scientific innovation and collective perseverance.

Get Sample Of This Report @ https://www.snsinsider.com/sample-request/3384

Market Scope & Overview

The research looks into the major variables affecting the expansion of the global market. The report used a bottom-up approach to gather and forecast data for a wide range of industrial verticals and end-user industries, as well as their reach across several categories, in order to determine the overall size of the Spinal Muscular Atrophy Treatment Market throughout the forecast period. Market actors may use market data to create plans to improve their competitive position.

The Spinal Muscular Atrophy Treatment Market research report covers all of these topics in great detail, including the Porter's Five Forces analysis, significant segments, drivers, opportunities, and the competitive environment. For business experts, stakeholders, investors, VPs, and newcomers who want to learn more about the company and formulate a competitive strategy, this study is an excellent resource.

Market Segmentation Analysis

By Type

Type 1

Type 2

Type 3

Type 4

By Treatment

Gene Therapy

Drug

By Drug

Spinraza

Zolgensma (AVXS-101)

Evrysdi

Others

By Route of Administration

Oral

Injection

COVID-19 Impact Analysis

Due to the COVID-19 lockout, it was necessary to create original strategies for dealing with future occurrences while sustaining steady growth. The market research report also provides advice for overcoming pandemic-like situations and lessening their harmful effects. The Spinal Muscular Atrophy Treatment Market was significantly impacted by the COVID-19 epidemic. Due to delays in new developments, the industry has also been suspended internationally.

Regional Outlook

With a focus on North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa, the Spinal Muscular Atrophy Treatment Market  research report digs into market aspects including estimations for total price from top manufacturers and trends toward advancement in various regions of the world.

Competitive Analysis

The research report offers a complete analysis of the worldwide Spinal Muscular Atrophy Treatment Market and suggests important adjustments that market players should take into account when developing their business plans. To gain market dominance, these companies have used partnerships, product development, joint ventures, mergers and acquisitions, diversification, and joint ventures.

Key Reasons to Purchase Spinal Muscular Atrophy Treatment Market Report

To identify important geographic regions and leading nations that have a substantial impact on market revenue, the researchers conduct geographic study.

Prospect information may be used by market participants to evaluate potential and formulate their next moves.

Report Conclusion

Manufacturers, distributors, dealers, and policymakers may use the data from the market research report to assess which industry sectors should be prioritized in the upcoming years in order to plan investments and take advantage of the Spinal Muscular Atrophy Treatment Market expansion.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Diabetic Neuropathy Market Trends

Smart Contact Lenses Market Size Trends

Lymphoma Treatment Market Trends

Veterinary Vaccine Adjuvants Market Trends

Medical Electrodes Market Trends

[trinitydigest]

Geographic Atrophy Market Size in the 7MM is expected to grow by 2034, as per DelveInsight

http://dlvr.it/T5wl4n

[columbianewsupdates]

Geographic Atrophy Market Size in the 7MM is expected to grow by 2034, as per DelveInsight

http://dlvr.it/T5wcJQ

[conversationpoint]

Geographic Atrophy Market Size in the 7MM is expected to grow by 2034, as per DelveInsight

http://dlvr.it/T5wcFK

[universalnewspoint]

Geographic Atrophy Market Size in the 7MM is expected to grow by 2034, as per DelveInsight

http://dlvr.it/T5wbBH

[health-views-updates]

The Future of the Geographic Atrophy Market: Trends and Challenges

Geographic Atrophy Market Outlook, Scope & Overview:

Industry reports indicate that the geographic atrophy (GA) market is projected to grow at a CAGR of 7.2% over the forecast period 2023-2030.

Technological Advancements to Drive Growth of Global Geographic Atrophy Market

The adoption of advanced diagnostic and therapeutic solutions for geographic atrophy will continue to influence global market revenues. Healthcare providers and pharmaceutical companies are increasingly focusing on innovative treatments and early diagnosis methods to manage and treat geographic atrophy, a progressive and irreversible condition that leads to the degeneration of the retina.

As a treatment segment, emerging therapies currently hold a significant potential share of the global geographic atrophy market. This segment is anticipated to grow at a year-over-year rate of 7.2% over the forecast period, driven by the increasing prevalence of GA and the rising investment in research and development for effective therapies.

Get a Free Sample Report of Vitamins Market: https://www.snsinsider.com/sample-request/2480 

Geographic Atrophy Market Dynamics

Drivers:

The geographic atrophy market is witnessing significant growth due to the rising prevalence of age-related macular degeneration (AMD), of which GA is an advanced form. The growing elderly population, increasing awareness about retinal diseases, and the development of innovative treatment options are key factors driving the adoption of GA therapies worldwide. Additionally, advancements in imaging technologies and diagnostic tools are further propelling market growth by enabling early detection and intervention.

Restraints:

Despite the growth potential, challenges such as the high cost of emerging therapies, limited treatment options, and the complexity of clinical trials for GA are hindering the widespread adoption of geographic atrophy treatments. Moreover, the chronic nature of the disease and the need for long-term management pose additional challenges to market expansion.

Geographic Atrophy Market Outlook

The proven benefits of early diagnosis and innovative treatments in managing geographic atrophy have contributed to the market's growth. The geographic atrophy market is expected to witness increased adoption of advanced therapies across major healthcare markets, including North America, Europe, and Asia Pacific, driven by advancements in medical research and the growing focus on improving patient outcomes.

Global Geographic Atrophy Market

The rise in demand for geographic atrophy treatments in developed and emerging markets is expected to drive market growth over the forecast period. North America currently holds a significant market share in the global geographic atrophy market, with the US being a key contributor to market revenues. Europe and Asia Pacific regions are also experiencing rapid adoption of GA therapies, supported by favorable regulatory frameworks and increasing investments in healthcare infrastructure.

Key Players in the Geographic Atrophy Market

Leading companies in the geographic atrophy market include Apellis Pharmaceuticals, IVERIC bio, Roche, and Alkeus Pharmaceuticals. These companies are at the forefront of developing and commercializing advanced therapies and diagnostic tools for geographic atrophy, aiming to improve patient quality of life and slow disease progression.

In conclusion, the global geographic atrophy market is poised for steady growth over the forecast period, driven by technological advancements, increasing prevalence of retinal diseases, and the expanding adoption of innovative therapies and diagnostic solutions in managing geographic atrophy

Other Trending Reports

Nicotine Replacement Therapy Industry Growth

Dry Age-Related Macular Degeneration Industry Growth

Neurovascular Devices Industry Growth

Artificial Intelligence in Drug Discovery Industry Growth

[rohans18]

Johnson Neuroectodermal Syndrome Market Analysis and Forecast to 2028

Global Johnson Neuroectodermal Syndrome Market, By Drug Class (Immunomodulators, Interferons, Decarboxylase Inhibitors, Dopamine Agonists and Others), Disease Indication (Multiple Sclerosis, Parkinson’s Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA) and Others), Route of Administration (Oral, Injection, Transdermal), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

In the consistent Johnson Neuroectodermal Syndrome market research report, industry trends are put together on macro level with which clients can figure out market landscape and possible future issues about Johnson Neuroectodermal Syndrome industry. The scope of this market report include but is not limited to latest trends, market segmentation, new market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target market analysis, insights and innovation. The report presents with the CAGR value fluctuations for the specific forecasted period which helps decide costing and investment strategies. An influential Johnson Neuroectodermal Syndrome market report brings precise and exact market research information that drives business into the right direction.

Key Players

The major players covered in the Johnson Neuroectodermal Syndrome market report are BioHorizons IPH, Inc., Floss Locations, Dr. Fresh LLC, Colgate-Palmolive Company, GlaxoSmithKline plc, 3M Company, Ultradent Products Inc., Bausch Health Companies Inc., Dentsply Sirona, Medtronic PLC, Zimmer Biomet Inc., Sunstar Suisse S.A. and PatientPop.Inc among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-johnson-neuroectodermal-syndrome-market

The research studies entailed in the winning Johnson Neuroectodermal Syndrome market report supports to estimate several important aspects that includes but are not limited to investment in a rising market, success of a new product, and expansion of market share. The strategies underlined here mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that boost footprints in this market. Several other factors such as import, export, gross margin, price, cost, and consumption are also analyzed under the section of production, supply, sales and market status.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Johnson Neuroectodermal Syndrome Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

[kritikarehani]

Geographic Atrophy Market

The total diagnosed cases of Geographic Atrophy in the 7MM were found to be 2,516,401 in 2017. 

The market size of Geographic Atrophy in 7MM was USD 276 Million in 2017, which is expected to grow during the study period, i.e., 2017–2030.

Increasing prevalence rate, emerging novel treatment options, and patient-friendly dosage regimes are some of the key factors expected to drive the Geographic Atrophy Market forward in the coming years.

The key players in the Geographic Atrophy Market includes Apellis Pharmaceuticals, IVERIC bio, Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Gyroscope Therapeutics Limited, Regenerative Patch Technologies LLC, Roche, Ionis Pharmaceuticals, Cell Cure Neurosciences, Janssen Pharmaceutica and others. 

For more detailed information on Geographic Atrophy Market, visit: 

https://www.delveinsight.com/report-store/geographic-atrophy-ga-market

[marketinsightshare]

Neurodegenerative Disease Market - Forecast(2022 - 2027)

The Neurodegenerative Disease Market size is estimated to reach $49,218 million by 2027. Furthermore, it is poised to grow at a CAGR of 3.9% over the forecast period of 2022-2027. Neurodegenerative diseases are a set of brain disorders that cause the structure and function of neurons in the central nervous system (CNS) and peripheral nervous system (PNS) to deteriorate over time (PNS). Several drugs are currently available to help people lessen physical or mental symptoms and improve their quality of life. Furthermore, researchers are concentrating their efforts on developing molecular diagnostics, particularly biomarkers and imaging spectroscopy, in order to detect and diagnose neurodegenerative illnesses at an early stage and halt their progression. The impact of COVID-19 on the neurodegenerative disease market is projected to be significant, as the pandemic has disrupted clinical trial, research and development, and pipeline product workflows, resulting in relatively modest growth during the pandemic despite a solid late-stage product pipeline. Despite the pandemic the market is forecasted to gradually recover and grow in the years of forecast. The companies with higher funding and revenue are investing more into R&D with development of unique neurodegenerative disease drugs for the various neurodegenerative indications while expanding to new geographic locations through its sales channel expansion. Recently, companies are focusing on making continuous investment across the business to in order to build and maintain the pipeline of new drugs for therapeutics. Companies are also predicted to acquire, grow the foreign market revenue and continue to get timely regulatory approvals. Rising prevalence of Alzheimer disease, increasing public awareness, and a strong product pipeline for neurodegenerative disease treatment are some of the factors driving the drug Industry forward in the projected period of 2022-2027.

Report Coverage

The report: “Neurodegenerative Disease Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Neurodegenerative Disease Market.

By Drug Class- N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Acetylcholinesterase (AChE) Inhibitors, Dopamine Agonists and Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor.

By Indications- Parkinson’s Disease, Huntington Disease, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Spinal Muscular Atrophy (SMA) and Others.

By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

Geographically, North America held a dominant market share in the year 2021. The growing geriatric population in the US is increasing the prevalence of neurodegenerative diseases as age is the best known risk factor for such diseases. The geriatric population was estimated to be around 65 million in 2020. This is projected to increase by 18 million between 2020 and 2030 and it is estimated that approximately 1 in every 5 Americans will be 65 or more by 2030..

The surge in neurodegenerative diseases in the US owing to the rising geriatric population is increasing the demand for effective neurodegenerative disease therapies for treating the disease and suppressing symptoms. In addition, it has also resulted in an increase in public R&D expenditure towards drug research, which will further contribute to the market growth. For instance, the Federal Alzheimer's and Dementia Research Funding increased from $2.8 billion in 2019 to $3.2 in 2021.

A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Neurodegenerative Disease Market Report.

Neurodegenerative Disease Market- Geography (%) for 2021

For More Details on This Report - Request for Sample

Neurodegenerative Disease Market Segmentation Analysis- By Drug Class

The neurodegenerative disease market based on drug class can be further segmented into N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Acetylcholinesterase (AChE) Inhibitors, Dopamine Agonists and Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor. Immunomodulators held a dominant market share in the year 2021. Immunomodulators provides very effective therapy options for a variety of autoimmune and neurodegenerative illnesses. Furthermore, the growing presence of important companies is likely to raise patient and physician awareness of the benefits of immunomodulators. As they strive to obtain a competitive advantage in the market, they are developing novel immunomodulators to treat a variety of chronic conditions.

However, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors is estimated to be the fastest-growing, with a CAGR of 13.3% over the forecast period of 2022-2027. It is owing to increase in number of patients with bipolar diseases, schizophrenia, and Huntington’s disease and other neuropsychiatric disorders undergoing long-term medical treatments with antipsychotic medication. Furthermore, throughout the projected period, investigational research for the discovery of novel therapies using VMAT2 inhibitors to treat Huntington disease are expected to drive demand.

Neurodegenerative Disease Market Segmentation Analysis- By Indications

The neurodegenerative disease market based on indications can be further segmented into Parkinson’s Disease, Huntington Disease, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Spinal Muscular Atrophy (SMA) and Others. Multiple Sclerosis held a dominant market share in the year 2021. Recently, more than 4,00,000 people in U.S. are suffering from multiple sclerosis which is rising the adoption of various types of drug class, so the demand for neurodegenerative drugs is expanding. Apart from this, the breakout of the COVID-19 pandemic has had a significant impact on the growth of the multiple sclerosis medications, as it has disrupted the supply chains of numerous important participants in the industry. For example, Biogen announced that sales of one of its important medications, TECFIDERA, which is used to treat multiple sclerosis, fell by 13% in 2020 compared to the previous year such factors are predicted to have a minor impact on market expansion.

However, Huntington Disease is estimated to be the fastest-growing, with a CAGR of 13.2% over the forecast period of 2022-2027. It is owing to various factors such as greater adoption of novel drugs, expanded R&D activity, an increase in the target population, and supportive regulatory measures are all driving the Huntington's Disease incidence. Reportedly, more than 20 drugs are in various phases of clinical trials for the treatment of Huntington's disease.

Neurodegenerative Disease Market Segmentation Analysis- By Geography

The neurodegenerative disease market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 3.1% in the year 2021 as compared to the other counterparts. It is owing to increasing prevalence of neurodegenerative diseases such as Alzheimer diseases, Huntington disease etc. According to the Centers for Disease Control (CDC), Alzheimer's disease is the 6th leading cause of death among US adults. In 2020, it is estimated that more than 5.8 million Americans aged 65 years or older are suffering from Alzheimer’s disease. This is projected to reach 7.7 million by 2030. Meanwhile, according to the Parkinson’s Foundation Prevalence Project, the prevalence of Parkinson’s in the US is predicted to rise from 930,000 in 2020 to 1.2 million by 2030.

Neurodegenerative Disease Market Drivers

Rising prevalence of Alzheimer disease have readily aided the market growth

Alzheimer's disease is a degenerative neurological disease and the most common form of dementia, characterised by memory loss, loss of thinking skills, and difficulties with problem-solving and language. Alzheimer's disease symptoms appear gradually over many years and eventually grow more severe. According to the World Health Organization (WHO), in 2021 over 50 million individuals suffer from dementia, a frequent form of Alzheimer's disease, with 10 million new cases diagnosed each year. The increased prevalence of these disorders also drives the development of various medications. Besides, the market is growing as people become more aware of the drug therapies for Alzheimer's disease around the world. Furthermore, rising awareness of the different novel treatment alternatives, is also helping to fuel the rise of Alzheimer's Drugs.

Availability of robust pipeline of drugs for neurodegenerative disease treatment is driving the market growth

Availability of robust pipeline of drugs for neurodegenerative disorders is forecasted to drive growth of the global Neurodegenerative Disease Market. Recently, in 2021, GlaxoSmithKline Plc in collaboration with Alector Inc. to develop antibody-based treatments for Parkinson's, Alzheimer's and other similar diseases. This collaboration deals worth up to $2.2 billion which efforts to build a robust pipeline of drugs.

Neurodegenerative Disease Market Challenges

High cost of treatment are some of the factors impeding the market growth

The extremely high cost is anticipated to hamper market growth as it limits the access of quality treatment to the middle and low-income population countries. For instance, in U.S. the average annual medical cost for the treatment of Multiple Sclerosis (MS) can reach more than $70,000. This is highly expensive as the country’s median household income in 2020 was only $67,521.

Neurodegenerative Disease Market Competitive Landscape

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Neurodegenerative Disease Market. The top 10- Neurodegenerative Disease Market companies are-

Biogen Inc.,

F. Hoffman La Roche Ltd.,

Merck KGaA,

Novartis AG,

Sanofi,

Teva Pharmaceuticals Industries Ltd.,

Orion Corporation,

H. Lundbeck A/S.,

Sun Pharmaceutical Industries Ltd.,

UCB S.A.

Recent Developments

In May 2021, Biogen Inc. and Envisagenics announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases. As part of the collaboration, Biogen will leverage Envisagenics’ proprietary artificial intelligence (AI)-driven RNA splicing platform, SpliceCore®, to define and understand the regulation of different RNA isoforms in CNS cell types.

In August 2020, Roche announced that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older. This is predicted to drive the SMA indication segment.

In February 2020, Novartis announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company’s Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults.

[mrfrblogresearch02]

Orphan Drugs Market Outlook: Post Covid-19 Scenario by 2027

Global Orphan Drugs Market - Overview

The global Orphan Drugs Market Size is growing exponentially owing to unmet needs for rare diseases and the growing investment in research and development are the major factor driving the orphan drugs Market.

The global orphan drug market was estimated to be $93 billion in 2015 and is projected to reach $200 billion. Orphan drugs represented 35% of the industry’s new drug approvals. The orphan drugs are disorders that affects a small percentage of the population. The major driving factor for the growth are low marketing cost, extensive exclusivity, government support leading to economic, legislative and tax benefits, new technology development such as hybridoma, gene mapping, and DNA recombinant.

A pharmaceutical product aimed at rare diseases or disorders is known as an orphan drug. The Orphan Drug Act of 1983 has been financially incentivised through US law for the development of orphan drugs. According to the National Organization for Rare Disorders (NORD) established an act which estimates that approximately 30 million Americans suffer from 7,000 different types of rare diseases. Prior to the incorporation of Orphan Drug Act, 38 drugs from orphan category were already approved. The success of this act in the US led to its adoption in other key markets, most notably by the European Union in the early 2000 and in 1993 for Japan.

There are an estimated 30 million in Europe and 350 million people worldwide suffering from rare diseases. Almost half of the rare diseases are genetic in nature, with 50% of children being affected. Approved drug treatment for about 5% of rare diseases are available that accounts to only 326 new drugs being approved by the FDA and are supplied in the market.

The competition from generics and biosimilars, safety concern, extensive post market surveillance, and costly clinical trials are some factors that threats the growth of this market. The hindrance of commercialization and distribution channels can also be due to the differential availability of the product in the developed and developing countries due to social and economic factors.

The global market for vacuum blood collection tube is expected grow at a CAGR of 11.6% over the forecasted period.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2312

Industry Updates:

Jan, 2017 Acucela Inc. received orphan drug FDA approval for emixustat for treating Stargardt disease. This approval was expected to be crucial for the treatment of this rare genetic disease.

Nov, 2015 Astellas Pharma acquired Ocata Therapeutics to increase its product portfolio for treatment of retinal disorders including Stargardt disease and age-related macular degeneration

June, 2015 Bayer Healthcare and Johns Hopkins University entered into a five year collaboration to develop for the treatment of Stargardt's disease, retinal vein occlusion, diabetic macular edema, age-related macular degeneration, and geographic atrophy.

March, 2014 Santen Pharmaceuticals signed a pact with TRACON pharmaceuticals to develop and commercialize Tracon's anti-VEGF product TRC105, an orphan drug category for the treatment of various eye related disorder

April, 2012 Baush and Lomb acquired Ista Pharmaceuticals for increasing its customer base and acquiring pipline drugs for the treatment of Stargardt disease.

Global Orphan Drugs Market - Regional Analysis:

Depending on geographic region, Globally North America is the largest market for orphan drugs. Factors such as high product demand and the increasing government incentives are expected to promote market growth in the US region, which is considered to be the highest revenue-generating region in the Americas.

Europe is the second-largest market for Global orphan drugs. The future market for orphan drugs is anticipated to be dominated by the developed regions with developing regions act as a supporting pillar to its growth.

Asia Pacific will be the fastest growing regional market and is likely to be the key to the future. Middle East & Africa is expected to have limited but steady growth in the market.

Global Orphan Drugs Market - Company Analysis:

This market is highly fragmented and is dominated by five major vendors including Bristol-Mayer Squibb Company, Celgene Corporation, F. Hoffmann La Roche, Novartis AG, and Pfizer Inc. as they have extensive product portfolios. Factors such as the high regulatory barriers, patent expiry of branded drugs, stringent rules and regulations, and decreased R&D productivity, pose significant challenges to the vendors during the forecast period.

Other prominent players in the value chain include AstraZeneca plc, AbbVie Inc., Aegerion Pharmaceuticals, Inc., GlaxoSmithKline plc, Vertex Pharmaceuticals, Merck & Co., Inc., Boehringer Ingelheim GmbH, Amgen Inc., and Actelion Pharmaceuticals Ltd.

Browse Detailed TOC with COVID-19 Impact Analysis at:

https://www.marketresearchfuture.com/reports/orphan-drugs-market-2312

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

Bottom of Form